BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Aradigm Corporation 

3929 Point Eden Way

Hayward  California  94545  U.S.A.
Phone: 510-265-9000 Fax: 510-265-0277


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology


Collaborations

Novo Nordisk A/S  Commercial agreement to develop AERx technology for the delivery of insulin, insulin analogues and other glucose-lowering agents for diabetes management.

GlaxoSmithKline  Agreement to develop AERx technology for the delivery of morphine and fentanyl for pain management.

University Of Torino  Aradigm has additional undisclosed partnerships with both platforms looking at developmental and marketed products.

GlaxoSmithKline (North Carolina) 





 Company News
Aradigm Corporation (ARDM) To Host Analyst Meeting And Webcast On August 12 In New York City 8/6/2014 9:50:34 AM
Aradigm Corporation (ARDM) To Host Corporate Update Conference Call On June 26 6/25/2014 8:52:46 AM
Aradigm Corporation (ARDM) Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 6/23/2014 11:44:16 AM
Aradigm Corporation (ARDM) Receives $5 Million Milestone For Dosing Of The First Patient In Phase 3 Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis 6/3/2014 8:40:03 AM
FDA Grants QIDP Designation To Aradigm Corporation (ARDM)’s Inhaled Antibiotic 5/20/2014 8:56:27 AM
Results From Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm Corporation (ARDM)’s Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2014 International Conference 4/15/2014 6:51:07 AM
Aradigm Corporation (ARDM) Announces Fourth Quarter 2013 And Full Year Financial Results 3/13/2014 6:50:37 AM
Aradigm Corporation (ARDM) to Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 On February 11 2/4/2014 7:47:10 AM
Aradigm Corporation (ARDM) Announces Appointment Of Dr. Juergen Froehlich As Chief Medical Officer 11/19/2013 8:33:56 AM
Sigma-Tau PharmaSource, Inc. and Aradigm Corporation (ARDM) Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin 9/16/2013 10:00:36 AM
12345678910...